These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 35428853)

  • 1. Risk of sustained SARS-CoV-2 transmission in Queensland, Australia.
    Sanz-Leon P; Stevenson NJ; Stuart RM; Abeysuriya RG; Pang JC; Lambert SB; Kerr CC; Roberts JA
    Sci Rep; 2022 Apr; 12(1):6309. PubMed ID: 35428853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.
    Sanz-Leon P; Hamilton LHW; Raison SJ; Pan AJX; Stevenson NJ; Stuart RM; Abeysuriya RG; Kerr CC; Lambert SB; Roberts JA
    Philos Trans A Math Phys Eng Sci; 2022 Oct; 380(2233):20210311. PubMed ID: 35965469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variants.
    Blanquart F; Hozé N; Cowling BJ; Débarre F; Cauchemez S
    Elife; 2022 May; 11():. PubMed ID: 35587653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
    Milne GJ; Carrivick J; Whyatt D
    BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.
    Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C
    Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact of reopening schools in the UK in early 2021 in the presence of the alpha variant and with roll-out of vaccination against SARS-CoV-2.
    Panovska-Griffiths J; Stuart RM; Kerr CC; Rosenfield K; Mistry D; Waites W; Klein DJ; Bonell C; Viner RM
    J Math Anal Appl; 2022 Oct; 514(2):126050. PubMed ID: 35153332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulating Transmission Scenarios of the Delta Variant of SARS-CoV-2 in Australia.
    Chang SL; Cliff OM; Zachreson C; Prokopenko M
    Front Public Health; 2022; 10():823043. PubMed ID: 35284395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-estimated relationship between elementary school-related SARS-CoV-2 transmission, mitigation interventions, and vaccination coverage across community incidence levels.
    Giardina J; Bilinski A; Fitzpatrick MC; Kendall EA; Linas BP; Salomon J; Ciaranello AL
    medRxiv; 2021 Nov; ():. PubMed ID: 34816266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
    Christie A; Brooks JT; Hicks LA; Sauber-Schatz EK; Yoder JS; Honein MA;
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(30):1044-1047. PubMed ID: 34324480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Household transmission of the Delta COVID-19 variant in Queensland, Australia: a case series.
    Wright E; Pollard G; Robertson H; Anuradha S
    Epidemiol Infect; 2022 Oct; 150():e173. PubMed ID: 36192365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
    Mancuso M; Eikenberry SE; Gumel AB
    Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.
    Nygaard U; Holm M; Hartling UB; Glenthøj J; Schmidt LS; Nordly SB; Matthesen AT; von Linstow ML; Espenhain L
    Lancet Child Adolesc Health; 2022 Jul; 6(7):459-465. PubMed ID: 35526537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opening up safely: public health system requirements for ongoing COVID-19 management based on evaluation of Australia's surveillance system performance.
    Lokuge K; D'Onise K; Banks E; Street T; Jantos S; Baptista M; Glass K
    BMC Med; 2022 Apr; 20(1):157. PubMed ID: 35421989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the peak: Point prevalence of SARS-CoV-2 using randomised sampling.
    Wattiaux AL; May F; Allen T; Bladen T; Pery B; McHugh L; Slinko V; Sykes A; De Silva L; Bajra J; Andrews R; Khandaker G
    Commun Dis Intell (2018); 2022 Apr; 46():. PubMed ID: 35469557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.
    Madewell ZJ; Yang Y; Longini IM; Halloran ME; Dean NE
    JAMA Netw Open; 2022 Apr; 5(4):e229317. PubMed ID: 35482308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.